Literature DB >> 560649

Memory and cognitive function in man: does the cholinergic system have a specific role?

D A Drachman.   

Abstract

Interference with cholinergic function produces disruption of memory/cognitive (M/C) performance in both animals and man. It is uncertain whether this disruption is due to a specific relation of cholinergic neurons to M/C functions, or whether the effect is nonspecific, resulting either from alteration of alertness and attention, or from a "mass action" effect, with loss of functioning neurons. Scopolamine was given to normal subjects to produce an M/C impairment. Half the test subjects then received physostigmine and half d-amphetamine. Physostigmine, a pharmacologic antagonist of scopolamine, markedly improved M/C functions; amphetamine failed to produce M/C improvement, although alertness was improved, and activity in catecholaminergic neurons presumably increased. This comparison supports a specific role for cholinergic neurons in M/C processes. Possible mechanisms of cholinergic neural functioning in memory include plasticity of cholinergic synapses, as well as other acetylcholine-depended operations of the limbic system crucial to memory.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 560649     DOI: 10.1212/wnl.27.8.783

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  83 in total

1.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Acute nicotinic blockade produces cognitive impairment in normal humans.

Authors:  P A Newhouse; A Potter; J Corwin; R Lenox
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Cholinergic control in developing prefrontal-hippocampal networks.

Authors:  P Christoph Janiesch; Hanna-Sophie Krüger; Beatrice Pöschel; Ileana L Hanganu-Opatz
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

4.  Pattern separation and pattern completion in Alzheimer's disease: evidence of rapid forgetting in amnestic mild cognitive impairment.

Authors:  Brandon A Ally; Erin P Hussey; Philip C Ko; Robert J Molitor
Journal:  Hippocampus       Date:  2013-08-14       Impact factor: 3.899

5.  Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals.

Authors:  Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Lynda T Wells; Christopher L Wallace; Michael A Dawes; Lei Liu; Xin-Qun Wang
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-09-15       Impact factor: 5.067

6.  Comparison of error patterns produced by scopolamine and MK-801 on repeated acquisition and transition baselines.

Authors:  J Cohn; J M Ziriax; C Cox; D A Cory-Slechta
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers.

Authors:  A Patat; M J Klein; A Surjus; M Hucher; J Granier
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Effects of the hydro-alcoholic extract of Nigella sativa on scopolamine-induced spatial memory impairment in rats and its possible mechanism.

Authors:  Mahmoud Hosseini; Toktam Mohammadpour; Reza Karami; Ziba Rajaei; Hamid Reza Sadeghnia; Mohammad Soukhtanloo
Journal:  Chin J Integr Med       Date:  2014-03-02       Impact factor: 1.978

9.  Choline acetyltransferase and acetylcholinesterase abnormalities in senile dementia: importance of biochemical measurements in human post-mortem brain specimens.

Authors:  S Sorbi; P Antuono; L Amaducci
Journal:  Ital J Neurol Sci       Date:  1980-03

Review 10.  Estrogen therapy and cognition: a review of the cholinergic hypothesis.

Authors:  Robert B Gibbs
Journal:  Endocr Rev       Date:  2009-12-17       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.